中文摘要：

生物机体内天然存在许多受体与配体，它们之间亲和结合力远远高于抗体亲和力（Kd=10^-8～10^-9）．本实验根据VEGFR和VEGF之间的高亲和力（Kd=1．6×10^-11），以新生血管细胞表面的VEGFR为靶点，设计VEGF-hFc融合蛋白作为靶向抗肿瘤药物．在本实验中构建peDNA3．1-IgGIeader—VEGF-hFc重组载体，转染CH0／dhFr一细胞真核表达融合蛋白VEGF-hFc，并通过ProteinA纯化．使用A549细胞构建人非小细胞肺癌裸鼠肿瘤模型，小鼠静脉注射10μgVEGF-hFc融合蛋白用以抗肿瘤研究．连续给药4次后，肿瘤生长曲线表明，与对照组相比，实验组小鼠的肿瘤生长得到明显的抑制甚至消退；数据统计显示，VEGF—hFc肿瘤抑制率达90%．

英文摘要：

There are lots of endogenous ligands and receptors, such as VEGF and VEGFR,whose affinity （Ka = 1.6 × 10^-11） is about 100 folds higher than that of antibody drugs （Ka = 10^-8-10^-9 ）. Based on the high affinity of between VEGFR and VEGF, a fusion protein VEGF-hFc was designed to target new blood vessel cells expressing VEGFR. In this research, a pcDNA3.1-IgG leader-VEGF-hFc eukaryotic expression vector was constructed and transfected into CHO/dhFr- cells. Fusion proteins were secreted by CHO/dhFr^- cells, followed by affinity purification. Homo non-small-cell lung carcinoma SCID mouse tumor model was constructed with A549 cells. To study the ability of this fusion protein to suppress tumor growth, mouse veins were injected with 10μg fusion proteins. After 4 administrations, compared with the control group, the growth curve of tumor suggests that the tumor of experimental group mouse was suppressed, and in some cases even eliminated. These data showed that VEGF-hFc can suppress tumor growth up to 90 %.